Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thymostimulin for advanced hepatocellular carcinoma
ISRCTN29319366Phase 2Completed
- Sponsor
- Martin-Luther-University Halle-Wittenberg (Germany)
- Start
- Jul 2000
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of thymostimulin in hepatocellular carcinoma (HCC), sponsored by Martin-Luther-University Halle-Wittenberg (Germany). Primary endpoints: Overall survival, 1-year survival and 2 more. Started Jul 2000; status: completed.
02
Drugs
thymostimulin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ISRCTN29319366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN29319366.